OTARMENI™ (lunsotogene parvec-cwha) suspension, for intracochlear infusion
7d agoNews
From the article
💡What is OTARMENI? ➡️It is a prescription #genetherapy for children & adults with severe‑to‑profound hearing loss caused by confirmed biallelic OTOF variants, with preserved outer hair cell function & no prior cochlear implant in the treated ear (2/n) 🔗 @sac-oac.bsky.social
Continue reading on otarmeni.comYou might also wanna read
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·2mo agoGene therapy restored hearing in deaf patients
news.ki.se·1y ago
Evaluating a New Software (OTOGUIDE) to Help Monitor Electrode Insertion During Cochlear Implant Surgery.
clinicaltrials.gov·1d ago
Improving Cochlear Implant Outcomes Through Modeling and Programming Strategies Based on Human Inner Ear Pathology
clinicaltrials.gov·3d ago
Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia
clinicaltrials.gov·7d ago
Dividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
aktiencheck.de
Comments
Sign in to join the conversation.
No comments yet. Be the first.